Meeting Highlights from 17th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

December 4-7, 2019
Los Angeles, CA

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2019) is a four-day, multidiscipinary continuing medical education meeting that covers the interrelated topics of diabetes, cardiovascular disease and hyperlipidemia, and obesity and energy balance. The mission is to provide insights into our current understanding and appliction of new treatments as the clinicial guidances and management strategies evolve 

This year, the kickoff session and a joint symposium with the Journal of Metabolism focused on research and clinical advances related to metabolic syndrome and metabolism. Thus, the program theme, Exploring New Frontiers in Metabolism—Tomorrow's Clinical Science Today.

Several prominment leaders in diabetes research were acknowledged with awards, including:

  • Zachary T. Bloomgarden, MD, clinical professor of medicine at the Icahn School of Medicine at Mount Sinai in New York City, and the editor-in-chief of the Journal of Diabetes, was recognized for his contributions to our understanding of the interplay between insulin resistance, diabetes, and cardiometabolic disease with the Gerald Reaven Distinguished Leader in Insulin Resistance Award
  • Robert Henry, MD, professor of medicine at the University of California at San Diego, and chief of Endocrinology, Metabolism & Diabetes at the Veterans Affairs Healthcare System was honored with the “Distinguished Leader in Insulin Resistance Award.”  

In seeking out clinically relevant topics that offer insights, advances or updated guidance to inform the care of patients with endocrinre-related conditions, EndocrineWeb has chosen to provide highlghts of the following presentations:

What's New in the Management of Congestive Heart Failure in Patients with Diabetes. This session on the status of congestive heart failure raised two important factors that require the attention of clinicians treating patients with type 2 diabetes.

The first concerned Heart Failure with Preserved Ejection Fraction in Diabetes: A Benign Marker of Accelerated Aging, presented by Mark Kearney, MD, and the signficance of testing at risk patients for their VO2 max, in a presentation: Beyond the Myocardium with Heart Failure, by Robert J. Chilton, DO.

More to come.......Please check back over the next few days

Last updated on
First Article From This Meeting:
Moving from High Risk to Low Risk Prevention of CVD Outcomes
close X
SHOW MAIN MENU
SHOW SUB MENU